Age: 49.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Inappropriate schedule of product administration, No adverse event, Wrong product administered
Clinical narrative: No Adverse Event; A bivalent vaccine was given to the patient instead of a monovalent as the patient needed primary series; Also the time between the two doses is outside of the two month recommendation; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (A bivalent vaccine was given to the patient instead of a monovalent as the patient needed primary series), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Also the time between the two doses is outside of the two month recommendation) and NO ADVERSE EVENT (No Adverse Event) in a 49-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7148B) for COVID-19 prophylaxis.    Co-suspect product included mRNA-1273 (Spikevax) (batch no. 057A22A) for COVID-19 prophylaxis.    No Medical History information was reported.   On 12-Dec-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 19-Jan-2023, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 19-Jan-2023, the patient experienced WRONG PRODUCT ADMINISTERED (A bivalent vaccine was given to the patient instead of a monovalent as the patient needed primary series) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Also the time between the two doses is outside of the two month recommendation). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse Event). At the time of the report, WRONG PRODUCT ADMINISTERED (A bivalent vaccine was given to the patient instead of a monovalent as the patient needed primary series), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Also the time between the two doses is outside of the two month recommendation) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for WRONG PRODUCT ADMINISTERED (A bivalent vaccine was given to the patient instead of a monovalent as the patient needed primary series) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Also the time between the two doses is outside of the two month recommendation).  For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for WRONG PRODUCT ADMINISTERED (A bivalent vaccine was given to the patient instead of a monovalent as the patient needed primary series) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Also the time between the two doses is outside of the two month recommendation).    Concomitant and treatment medications were not reported.  Patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.  It was reported that, bivalent vaccine was given to the patient instead of a monovalent as the patient needed primary series.  Patient received primary series of Moderna vaccine on 12-Dec-2022 and a Moderna bivalent booster on 19-Jan-2023, so didn't received full primary series.  The time between the two doses is outside of the two-month recommendation.